Krabbe Disease Clinical Trials and Treatments

Krabbe Disease is a lysosomal lipid storage disorder resulting from mutations in the GALC gene encoding galactocerebrosidase. This enzyme normally catalyzes the breakdown of galactocerebroside, a major galactose-containing lipid component of myelin. GALC deficiency leads to accumulation of galactocerebroside and its toxic metabolite psychosine in oligodendrocytes, Schwann cells, and macrophages.

The most common symptoms of Krabbe Disease include Infantile form: developmental regression, irritability, and spasticity from 3-6 months of age, Peripheral neuropathy with loss of sensation, Progressive visual loss and blindness, Seizures starting in infancy or childhood, Severe developmental delays and intellectual disability, among others. Approximately 1 per 100,000 to 1 per 200,000 live births globally; about 1 per 40,000 in the U.S.. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Krabbe Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Krabbe Disease emphasizes early intervention through hematopoietic stem cell transplantation, enzyme replacement therapy, and gene therapy approaches. The timing of treatment is critical, with the best outcomes coming from intervention before symptoms appear or in infants identified early through newborn screening.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Krabbe Disease. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

Krabbe Disease is caused by variants in the GALC gene.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. Approximately 1 per 100,000 to 1 per 200,000 live births globally; about 1 per 40,000 in the U.S. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Krabbe Disease looks at the GALC gene.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Krabbe Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Krabbe Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.